Behavior assessment tool measures pain in nonverbal ICU patients

Measuring pain levels in critically ill patients, especially in those who cannot communicate verbally, is crucial in administering care. A study published in PAIN introduces a new behavior pain assessment tool (BPAT) capable of evaluating pain levels through nonverbal cues.

Led by Céline Gélinas, RN, PhD, of McGill University in Montreal, the study measured effectiveness of the BPAT in evaluating pain in the intensive care unit (ICU). Many patients in the ICU are unable to communicate verbally due to their clinical condition, level of awareness, ventilation interference and sedation, leaving the tool to measure pain levels through observable behaviors such as facial expressions, verbal responses and muscle responses.

"Since none of those conditions precludes the perception of pain, it is essential that clinicians have valid and reliable pain assessment methods," Gélinas and coauthors write.

The BPAT, which is available in 12 languages, was tested in more than 4,800 procedures in 3,850 patients from 192 ICUs in 28 countries. Pain was measured on the BPAT eight-point scale and was found to correlate with the pain ratings made my patients capable of verbal communication. At the point pain levels surpassed 3.5, BPAT was accurate in identifying more severe pain levels and patients in need of additional pain medications. The study showed that facial grimacing was the most common for nonverbal pain indication followed by wincing, moaning, verbal complaints and clenched fists

"The BPAT was found to be reliable and valid for use in critically ill patients unable to self-report," Gélinas and colleagues conclude. "Valid behavioral pain scales are necessary to ensure appropriate assessment of pain and to guide decisions for pain management in this vulnerable population." 

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.